All News

RheumNow Podcast square

Faith and Miracle Larry

d Jack Cush, MD

This week on the podcast, Dr. Jack Cush recalls what life was like early on during COVID, from March to June of 2020.  During this time, his close friend, Larry, contracted COVID-19 and was hospitalized, intubated and put on mechanical ventilation for nearly 2 months.

Read Article
guidelines.recommendations.jpg

2022 EULAR Recommendations for ANCA-associated Vasculitis

d Jack Cush, MD

EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Read Article
Pills_0.jpg

Polypharmacy Increased in Psoriatic Arthritis

d Jack Cush, MD

Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA.

Read Article
DLE discoid lupus

A Pilot Trial of Anifrolumab in Discoid Lupus

d Jack Cush, MD

A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE). 

Read Article
immune.activity.cytokine.jpg

Itaconate - A Potential New Immunosuppressive

d EurekAlert!

Researchers have revealed the modulatory effect of the anti-inflammatory metabolite itaconate (ITA) on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases.

Read Article
Follow me today and tomorrow for @RheumNow Live 2023 Coverage! #RheumTwitter #RNL2023 https://t.co/sS6AoF1Dij
Eric Dein ericdeinmd ( View Tweet)
QD Clinic - RheumNow Live 2023 Preview https://t.co/T8VMyrL1Qz https://t.co/E90wsaqwaY

Links:

Dr. John Cush RheumNow ( View Tweet)
A Pilot Trial of Anifrolumab in Discoid Lupus A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE). https://t.co/sax8iHuljb https://t.co/71zqAzZViV

Links:

Dr. John Cush RheumNow ( View Tweet)
Itaconate - A Potential New Immunosuppressive Researchers have revealed the modulatory effect of the anti-inflammatory metabolite ITA on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases. https://t.co/1kaxHou8pz https://t.co/VLLAzgiYoM

Links:

Dr. John Cush RheumNow ( View Tweet)
Happy Match Day! Congratulations to all that have matched. #MATCHDAY2023

Dr. John Cush RheumNow ( View Tweet)

Follow my coverage tomorrow and Sunday! #RNL2023 RheumNow Live ⁦@RheumNow⁩ #RheumTwitter https://t.co/6cZHJxPltA
Eric Dein ericdeinmd ( View Tweet)
Multicenter study of 1516 MIS-C pts - Initial Rx: 13% recv anakinra (w/ or w/o) otherdrugs; 64% rx w/ IVIG & steroids, 16%IVIG alone, 4% steroids alone. Anakinra gave no short-term CV benefits over IVIG and glucocorticoids alone. https://t.co/IVaC5dXzs8

Links:

Dr. John Cush RheumNow ( View Tweet)

28 biomarkers studied in 259 SSc-ILD, 179 SSc-NO ILD, 172 IPF & 30 healthy controls. Composite biomarker index (w/ SP-D [surfactant prot. D], Ca15-3 [MUC1], & ICAM-1) strongly correlated w/ SSc-ILD (adj OR 12.7); independent of age, sex, smoking, PFTs https://t.co/F0iKFqcZoY https://t.co/Ao25N1DFIx

Links:

Dr. John Cush RheumNow ( View Tweet)
Transcriptomic studies of Rx Refractory #RA pts shows increased gene expression of plasmacytoid dendritic cells (pDC) (reflecting expansion of pDC precursors) correlated well w/ Rx resistance. Type I IFN negatively correlated w pre-DC gene expression https://t.co/japvTnuTNu https://t.co/ad6ofbg3cO

Links:

Dr. John Cush RheumNow ( View Tweet)
Open-label trial of Guselkumab (IL-23 inhib) in 20 moderate-to-severe hidradenitis suppurativa (HS) pts saw 65% with HiSCR response at wk 16. Yet phase IIB NOVA PBO-RCT showed GUS HiSCR response 45–51% (vs 39% PBO). GUS may only benefit subgroup of HS https://t.co/OxtFfyRMFk https://t.co/hnQyU0VWxg

Links:

Dr. John Cush RheumNow ( View Tweet)
Cost-Effective Use of Biological and Targeted Synthetic DMARDs An international task force of experts have developed evidence-based points to consider regarding the cost-effective use of b/tsDMARDs in the treatment of inflammatory rheumatic diseases. https://t.co/jpxQggd89T https://t.co/zjer5QTN3C

Links:

Dr. John Cush RheumNow ( View Tweet)
Optimal Timing of Elective Hip or Knee Arthroplasty https://t.co/Dz7qHxS5aO https://t.co/z7Q2oReEJs

Links:

Dr. John Cush RheumNow ( View Tweet)
Congratulations to Dr. Georg Schett (University of Erlangen) upon receiving the 2023 Gottfried Wilhelm Leibniz Prize - highest honor from the DFG, German Research Foundation. Dr. Schett is famed for research on inflammation, autoimmunity & osteoimmunology https://t.co/Wq0EvhtvLW https://t.co/AWwCVCt4cm

Links:

Dr. John Cush RheumNow ( View Tweet)
Lancet metanalysis shows pts infected w/ SARS-CoV2 are conferred very high degree of re-infx from pre-omicron variants, even after 40 weeks. Protection was lower for omicron BA.1 & declined over time. Protection from severe Dz was high for all variants. https://t.co/RNgYVWQfNo https://t.co/J8U37NYXPP

Links:

Dr. John Cush RheumNow ( View Tweet)
Carpal Tunnel - Steroid injection vs. Night Splinting A randomized trial conducted by the UK National Health Service, studied interventions in patients with CTS and found no advantage to either CTS CSIor NS as the initial treatment of CTS. https://t.co/05AADf55uB https://t.co/m07xxffSfv

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×